NKGen Biotech to Present on Troculeucel for Neurodegenerative Diseases at 4th Great Bay Cell and Gene Therapy Forum | NKGN Stock NewsStockTitan·Sep 15, 2026 at 04:05 AMNKGN-82.50%
NKGen Biotech to Present on Potential of Troculeucel in Neurodegenerative Diseases at Biologics Manufacturing Korea 2026 | NKGN Stock NewsStockTitan·Sep 10, 2026 at 04:05 AMNKGN-82.50%
NKGen Biotech amends convertible loan deal with AlpineBrook, adds USD 1.05 million notePUBT·Sep 2, 2026 at 09:03 PMNKGN-82.50%
NKGen Biotech Amends $5 Million BDW Loan, Pledging Real Estate as First-Lien CollateralTradingView·Jul 17, 2026 at 09:03 PMNKGN-82.50%
NKGen Biotech to Present at the 2026 BIOCHINA Global Forum on Troculeucel’s Potential in Alzheimer’s Disease and Other Neurodegenerative Conditions | NKGN Stock NewsStockTitan·Jul 2, 2026 at 04:05 AMNKGN-82.50%
NKGen Biotech Expands AlpineBrook Convertible Loan; Adds $412,500 Note at $0.08 and More SharesTradingView·May 21, 2026 at 09:23 PMNKGN-82.50%
NKGen Biotech Expands Clinical Trial Site Network for Alzheimer’s Disease Program Across U.S. to Improve Patient Access and Support Enrollment | NKGN Stock NewsStockTitan·May 19, 2026 at 04:05 AMNKGN-82.50%IBBQ-0.15%
07:30 ETPackGene to Present Advances in Scalable AAV Manufacturing, Analytical Innovation, and Novel Capsid Engineering at ASGCT 2026prnewswire·May 5, 2026 at 11:38 AMNKGN-82.50%PRTG0.00%
NKGen Biotech Secures Additional Convertible Financing and WarrantsTip Ranks·May 4, 2026 at 11:16 PMNKGN-82.50%XLV-0.01%
NKGen Biotech Announces Major Convertible Financing and Governance ShiftTip Ranks·Apr 21, 2026 at 10:10 PMNKGN-82.50%LABU-0.37%
